Pancreatic cancer (PC) is a growing global burden, remaining one of the most lethal
cancers of the gastrointestinal tract. Moreover, PC is resistant to various treatments such as
chemotherapy,
radiotherapy, and
immunotherapy. New
therapies are urgently needed to improve the prognosis of PC. Oncolytic virus (OV)
therapy is a promising new treatment option. OV is a genetically modified virus that selectively replicates in
tumor cells. It can kill
tumor cells without harming normal cells. The activation of
tumor-specific T-cells is a unique feature of OV-mediated
therapy. However, OV-mediated mono-therapeutic efficacy remains controversial, especially for metastatic or advanced patients who require systemically deliverable
therapies. Hence, combination
therapies will be critical to improve the therapeutic efficacy of OV-mediated
therapy and prevent
tumor recurrence. This review aims to investigate novel combinatorial treatments with OV
therapy and explore the inner mechanism of those combined
therapies, hopefully providing a new direction for a better prognosis of PC.